Last reviewed · How we verify
cefdinir (Omnicef)
Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Community-acquired pneumonia, Acute exacerbation of chronic bronchitis, Acute maxillary sinusitis.
At a glance
| Generic name | cefdinir (Omnicef) |
|---|---|
| Also known as | ABT-198, Omnicef, cefdinir |
| Sponsor | Abbott |
| Drug class | Third-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefdinir works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of common infections. The drug is bactericidal, meaning it kills bacteria rather than merely inhibiting their growth.
Approved indications
- Community-acquired pneumonia
- Acute exacerbation of chronic bronchitis
- Acute maxillary sinusitis
- Pharyngitis/tonsillitis
- Uncomplicated skin and skin structure infections
- Acute otitis media
Common side effects
- Diarrhea
- Vaginal yeast infection
- Nausea
- Headache
- Abdominal pain
- Rash
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Cefdinir Capsules 300 mg, Fasting (PHASE1)
- Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting (PHASE1)
- Cefdinir for Oral Suspension 250 mg/5mL, Fasting (PHASE1)
- Cefdinir Capsules 300 mg, Non-fasting (PHASE1)
- Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cefdinir (Omnicef) CI brief — competitive landscape report
- cefdinir (Omnicef) updates RSS · CI watch RSS
- Abbott portfolio CI